NCT06974851招募中3 期
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- Percentage Change in AHI from Baseline at Week 52 of Treatment
研究概览
简要总结
A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects with Obstructive Sleep Apnea (OSA) and Obesity
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant has provided informed consent and is willing and able to comply with the study protocol requirements to complete the study.
- •Age between 18 and 75 years, male or female, at the time of signing the informed consent form.
- •BMI ≥ 28.0 kg/m² at screening.
- •Has been on a controlled diet and exercise regimen for 3 months or more, with a weight change of ≤ 5.0 kg in the past 3 months.
- •Polysomnography (PSG) results at screening confirm OSA.
- •Female participants of childbearing potential and male participants with partners of childbearing potential agree to use highly effective contraception from the time of signing the informed consent form until 2 months after the last dose, with no plans for pregnancy or donation of eggs/sperm during this period. Female participants of childbearing potential must have a negative pregnancy test within 3 days prior to randomization and must not be breastfeeding.
排除标准
- •Laboratory Test Abnormalities:
- •Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 × upper limit of normal (ULN), or total bilirubin (TBIL) ≥ 2.0 × ULN.
- •Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula based on serum creatinine).
- •Thyroid-stimulating hormone (TSH) < 0.4 or > 6.0 mIU/L.
- •Other laboratory abnormalities judged by the investigator to potentially affect efficacy or safety assessments.
- •Clinically Significant ECG Abnormalities:
- •ECG findings deemed clinically significant by the investigator, including but not limited to myocardial infarction, severe arrhythmias (e.g., supraventricular tachycardia, atrial fibrillation, atrial flutter, second- or third-degree atrioventricular block, etc.), which may affect participant safety.
- •Poorly Controlled Blood Pressure:
- •Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg.
- •PHQ-9 Score ≥ 15:
- •Patient Health Questionnaire-9 (PHQ-9) score ≥
- •Medical History or Conditions Prior to Screening or Randomization:
- •Endocrine disorders or monogenic mutations causing obesity or hereditary obesity syndromes that may significantly affect weight.
- •Diabetes mellitus.
- •Diagnosis of central or mixed sleep apnea or Cheyne-Stokes respiration.
- •Respiratory or neuromuscular diseases judged by the investigator to potentially interfere with trial results.
- •Clinical abnormalities or diseases related to insomnia or excessive sleepiness (excluding OSA).
- •History of conditions affecting gastric emptying, long-term use of medications directly affecting gastrointestinal motility, severe gastrointestinal diseases, or prior gastrointestinal surgery.
- •History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treatment-requiring gallbladder disease.
- •Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).
- •Severe infections, significant trauma, or major/moderate surgery within 1 month prior to screening.
- •Severe cardiovascular or cerebrovascular events within 6 months prior to screening, including decompensated heart failure (NYHA Class III or IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmias, or cardiac surgeries such as coronary artery bypass grafting or percutaneous coronary intervention.
- •Malignancy in any organ system within the past 5 years, regardless of evidence of local recurrence or metastasis (except cured local basal cell carcinoma, cervical carcinoma in situ, and prostate carcinoma in situ).
- •Presence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other severe psychiatric disorders.
- •Known or suspected history of alcohol and/or drug abuse or drug addiction.
- •Acute or chronic hepatitis or other severe liver diseases (excluding non-alcoholic fatty liver disease).
- •Severe hematologic diseases (e.g., aplastic anemia, myelodysplastic syndrome, hemolytic anemia, sickle cell disease) or any condition causing hemolysis or red blood cell instability (e.g., malaria).
- •Autoimmune diseases requiring systemic corticosteroid or immunosuppressive therapy during the study period.
- •Medications or Treatments Prior to Screening:
- •Use of medications or treatments likely to cause significant weight gain or loss within 3 months prior to screening.
- •Medications or treatments judged by the investigator to potentially affect sleepiness assessments.
- •Prior or planned bariatric surgery (except liposuction performed more than 1 year ago).
- •Prior or planned endoscopic or device-based weight loss treatments, or device removal within the past 6 months (e.g., mucosal ablation, gastric artery embolization, intragastric balloons, duodenal-jejunal bypass sleeves).
- •Use of positive airway pressure (PAP) or other OSA treatments judged by the investigator to potentially interfere with study results (e.g., oral appliances, neurostimulation therapy), unless the participant is willing to discontinue such treatments 4 weeks prior to screening and during the study.
- •Requirement for supplemental oxygen.
- •Other Exclusion Criteria:
- •Participation in any drug or medical device clinical trial within 3 months prior to screening, defined as signing informed consent and using the investigational product (including placebo) or medical device, or still within 5 half-lives of the investigational drug (whichever is longer).
- •History of blood donation or blood loss ≥ 400 mL within 3 months prior to screening, or receipt of a blood transfusion within 3 months.
- •Planned surgery during the trial (except minor surgeries deemed by the investigator to not affect the trial).
- •Participants with mental incapacity or language barriers unable to fully understand or participate in the trial.
- •Any condition judged by the investigator to affect participant safety or interfere with the evaluation of trial results (medical, psychological, social, or geographical factors, etc.).
- •Investigators, research site staff, or other individuals directly involved in the execution of the protocol, and their immediate family members (e.g., spouse, legal partner, parents, children, or siblings). Employees of Hengrui Company are also excluded.
研究组 & 干预措施
Group 2: HRS9531placebo
Placebo Comparator
干预措施: HRS9531placebo (Drug)
Group 1: HRS9531
Experimental
干预措施: HRS9531 (Drug)
结局指标
主要结局
Percentage Change in AHI from Baseline at Week 52 of Treatment
时间窗: 52week
次要结局
- Changes in AHI Relative to Baseline After 52 Weeks of Treatment(52week)
- Proportion of Subjects with AHI <5.0 events/h, or AHI 5.0-14.0 events/h with Epworth Sleepiness Scale (ESS) ≤10 at Week 52 of Treatment(52week)
- Percentage Change in Body Weight from Baseline at Week 52 of Treatment(52week)
- Change in Epworth Sleepiness Scale (ESS) Score from Baseline at Week 52 of Treatment(52week)
- Proportion of Subjects Achieving ≥5%, ≥10%, ≥15%, and ≥20% Reduction in Body Weight from Baseline at Week 52 of Treatment(52week)
- Change in Body Weight and Body Mass Index (BMI) from Baseline at Week 52 of Treatment(52week)
- Change in systolic and diastolic blood pressure from baseline at Week 52 of treatment.(52week)
- Proportion of subjects reporting improvement in Patient Global Impression of Severity (PGIS)-OSA categories (sleepiness, fatigue, snoring) at Week 52 of treatment.(52week)
- Incidence of adverse events (AEs)(52week)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesType 2 DiabetesNCT06649344Fujian Shengdi Pharmaceutical Co., Ltd.884
已完成
1 期
Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy SubjectsType 2 DiabetesNCT06654960Fujian Shengdi Pharmaceutical Co., Ltd.20
已完成
2 期
Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes SubjectsType 2 DiabetesNCT05966272Fujian Shengdi Pharmaceutical Co., Ltd.199
进行中（未招募）
2 期
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic CardiomyopathyNCT06516068Shandong Suncadia Medicine Co., Ltd.42
已完成
2 期
Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesOverweight or ObesityNCT05881837Fujian Shengdi Pharmaceutical Co., Ltd.249